rolapitant - Generic Medications

Browse 1 brand name versions of rolapitant. Review brand names, dosage forms, strengths, and linked product records.

Varubi ROLAPITANT
TERSERA THERAPEUTICS LLC FDA Rx Only

VARUBI contains rolapitant, a substance P/neurokinin 1 (NK1) receptor antagonist. Rolapitant hydrochloride is chemically described as (5S,8S)-8- { [(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]}-8-phenyl-1,7-diazaspiro[4.5]decan-2-one hydrochloride. Its empirical formula is C 25 H 26 F 6 N 2 O 2 . HCl.H 2 O, and its structural formula is: rolapitant hydrochloride Rolapitant hydrochloride is a white to off-white powder, with a molecular weight of 554.95. Solubility of rolapitant hydrochloride in aqueous solution is pH-dependent and is more soluble at lower pH. Rolapitant has good solubility in common pharmaceutical solvents such as ethanol, propylene glycol and 40% hydroxypropyl beta-cyclodextrin. Each tablet contains 90 mg rolapitant (equivalent to 100 mg rolapitant hydrochloride) and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and pregelatinized starch. The tablets are coated in non-functional blue and clear coats. The tablet coating comprises the following inactive ingredients: FD&C Blue No. 2-Indigo Carmine Lake, polyethylene glycol, polysorbate 80, polyvinyl alcohol, talc, and titanium dioxide. Figure

About rolapitant Generic Drugs

This collection groups medications in our database under the generic name rolapitant. It currently includes 1 matching listing.

What You Can Review

Use this page to compare the set of products we have indexed for this generic name. Each result links to more detailed product information and related landing pages.

Safety Information

Always consult a qualified healthcare professional before starting, stopping, or switching any medication. The information on this page is educational and should not replace medical advice.

Medical Tools & Resources

← Back to search